In about an hour, the BioFire BJI Panel simultaneously targets a broad grouping of 31 causative pathogens and 8 antimicrobial resistance markers most often associated with bone and joint infections
*Investigational use only. Not for use in diagnostic procedures.
The BioFire BJI Panel tests for a comprehensive grouping of gram-positive and gram-negative bacteria, yeast, and antimicrobial resistance genes most often associated with bone and joint infections.
It takes just one syndromic test, one small sample of synovial fluid, and about an hour to get results on 39 clinically relevant targets.
(Subject to change)
SAMPLE TYPE:
0.2 mL of synovial fluid
PERFORMANCE:
Overall 90.6% Sensitivity and 99.8% Specificity1
PART NUMBER:
BioFire BJI Panel 30 Pouch Kit: RFIT-ASY-0139
GRAM-POSITIVE BACTERIA:
GRAM-NEGATIVE BACTERIA:
YEAST:
ANTIMICROBIAL RESISTANCE GENES:
Carbapenemases
• IMP
• KPC
• NDM
• Oxa-48-like
• VIM
Methicillin Resistance
• mecA/C and MREJ
Third-Generation Cephalosporin Resistance
• CTX-M
Vancomycin Resistance
• vanA/B
Conventional testing for bone and joint infections is complex, often requiring multiple patient samples, various send-out tests, and days of waiting for results. The BioFire BJI Panel is a rapid syndromic test that delivers comprehensive results in one easy-to-read report.
Using PCR technology, the BioFire BJI Panel offers fast sample-to-answer turnaround without sacrificing performance.
The BioFire BJI Panel identifies pathogens and antimicrobial resistance markers at the molecular level, encompassing the most common causes of bone and joint infections. It is not impacted by prior antibiotic use and targets difficult-to-grow anaerobes and fastidious pathogens.
Compared to conventional methods, it can help facilitate increased diagnostic yield and improved polymicrobial detection.
References: